Amylyx reports Phase 3 LUCIDITY trial shows 55% drop in hypoglycemic events
Amylyx Pharmaceuticals announced that its Phase 3 LUCIDITY trial of avexitide met the primary endpoint, cutting the composite hypoglycemic event rate by 55% versus placebo. The trial enrolled 78 adults with post‑bariatric hypoglycemia, randomised 3:2 to a daily 90 mg subcutaneous dose of avexitide or placebo, and achieved statistically significant reductions across all prespecified secondary endpoints. The company said it will file a New Drug Application by the end of 2026 and is targeting a commercial launch in 2027 if approved.
Why it matters
The company expects the NDA filing by year‑end to move avexitide toward potential FDA approval and a 2027 market launch, which could create a new revenue stream for Amylyx (the company says).
Key facts
- 1The trial reduced the composite hypoglycemic event rate by 55% versus placebo. tradingview.com
- 2Adjusted event rates were 0.55 events per week on avexitide and 1.24 events per week on placebo (p=0.0000034). mugglehead.com
- 3The study enrolled 78 adult participants with post‑bariatric hypoglycemia. mugglehead.com
- 4Participants were randomised 3:2 to avexitide 90 mg daily or placebo. biospace.com
- 5More than 90% of participants completed the 16‑week double‑blind phase (45/47 avexitide, 28/31 placebo). biospace.com
- 6Amylyx plans to submit an NDA by the end of 2026 and aims for a 2027 launch if approved. investing.com
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.